iStent® Trabecular Micro-Bypass: Add an Exciting New Glaucoma Technology to your Cataract Surgery
Cataract surgery and glaucoma therapy - all in one procedure.
Technology has always played an important role in eye care. Today, almost every aspect of vision is connected to a product or procedure that wasn't available even ten short years ago. Today, this includes managing your mild-to-moderate open-angle glaucoma: because now we are able to add another step for patients undergoing cataract surgery that allows you to treat your open-angle glaucoma in a completely new way. This is important because once diagnosed with glaucoma, you and most patients like you will spend the rest of your lives putting one, two or even three different kinds of drops in every day. Unfortunately, all of these drops will not only be inconvenient, but potentially irritating to the eye and very expensive. The iStent Trabecular Micro-Bypass Stent is designed to reduce your eye pressure and you can have it done at the same time you have cataract surgery.
iStent: The World's Smallest Medical Implant Delivers Big Results in Mild-to-Moderate Open-Angle Glaucoma
While mild-to-moderate open-angle glaucoma is very common, many people are unaware of their condition, especially in the early stages, when their vision may be unaffected. In many people, open-angle glaucoma is characterized by an increase in the intraocular pressure (IOP) of your eye. This pressure is caused by the buildup of fluid within the eye. Too much fluid raises pressure, which can cause the gradual loss of vision. And while glaucoma moves slowly, its damage is irreparable.
The world's tiniest medical device-iStent-is 20,000 times smaller than the intraocular lenses (IOL) used in your cataract surgery
. But the size of iStent is only part of its story. By increasing the eye's ability to drain fluid, this technology is designed to reduce the pressure in your eye.
Ask Dr. Scott Piette
or Dr. Stephen Tate
at New Vision Eye Center
if iStent for glaucoma eye surgery is right for you.
In a U.S. clinical study, 68% of glaucoma patients who received iStent remained medication free at 12 months while sustaining a target IOP of ≤ 21 mm Hg vs. only 50% of patients who underwent cataract surgery alone.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent® has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after "washout" of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.
The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of ≥ 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.
Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.
Schedule A Visit
If you experience any of the above symptoms, or you're in need of an eye exam, please contact our world-class eye care sm
office today at 772-257-8700